CER-1236

N/A

Report date: 2025/02/20 20:00:06

Base Information

Drug NameCER-1236
Drug Alias NameCER-1236
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionImmunologic cytotoxicityPhagocytes stimulantsT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesCERo Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCERo Therapeutics Holdings IncCERo Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursHematologic NeoplasmsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A